BenevolentAI Atopic Dermatitis Drug Fails To Deliver
Trk Inhibitor Does Not Significantly Reduce Itch and Inflammation
Executive Summary
The UK artificial intelligence drug development expert has reported disappointing findings from a Phase II trial of lead candidate BEN-2293 in atopic dermatitis.
You may also be interested in...
J.P. Morgan: BenevolentAI Aims To Stay Ahead Of The Chasing Pack
The UK firm's platform has been validated by the partnerships sealed with AstraZeneca and Merck KGaA and the development of an internal five-strong product pipeline, acting CEO Francois Nader told attendees at the J.P. Morgan Healthcare Conference.
BenevolentAI Still Bullish As CEO Shields Steps Down
BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.
BenevolentAI Goes Public In Europe’s Largest SPAC
The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.